Evidence map›Paper›PMID 40392415›Full record

ArticleUpdates in surgery2025

Prognostic factors for progression free survival in patients with medullary thyroid cancer: a multicenter cohort study.

Guibin Zheng, Jianing Liu, Hao Xu, Chaopeng Dong, Xianjiao Cao, Qingqing He, Guanyu Zhang, Wei Wang, Liquan Wang, Xiaoqing Yang and 8 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Guibin Zheng *Department of Thyroid Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, 264000, Shandong, China.ORCID http://orcid.org/0000-0002-9087-6502
Jianing Liu *Department of Thyroid Surgery, The Second Hospital of Shandong University, Jinan, 250033, Shandong, China.
Hao XuDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
Chaopeng DongDepartment of Breast and Thyroid Surgery, Heze Municipal Hospital, Heze, 274000, Shandong, China.
Xianjiao CaoDepartment of Thyroid and Breast Surgery, The 960th Hospital of People'S Liberation Army, Jinan, 250031, Shandong, China.
Qingqing HeDepartment of Thyroid and Breast Surgery, The 960th Hospital of People'S Liberation Army, Jinan, 250031, Shandong, China.
Guanyu ZhangDepartment of Breast and Thyroid Surgery, Jining No. 1 People's Hospital, Jining, 272002, Shandong, China.
Wei WangDepartment of Breast and Thyroid Surgery, Jining No. 1 People's Hospital, Jining, 272002, Shandong, China.
Liquan WangDepartment of Breast and Thyroid Surgery, Weifang People's Hospital, Weifang, 261000, Shandong, China.
Xiaoqing YangDepartment of Thyroid Surgery, Weihai Municipal Hospital, Cheeloo College of Medicine, Shangdong University, Weihai, 264200, Shandong, China.
Jiaqi LiuBreast and Thyroid Surgery Department, Zibo Central Hospital, Zibo, 255000, Shandong, China.
Min HaoDepartment of Breast and Thyroid Surgery, Dongying People's Hospital, Dongying, 257091, Shandong, China.
Kecheng XueDepartment of Thyroid Surgery, Linyi People's Hospital, Linyi, 276003, Shandong, China.
Guolou LiDepartment of Thyroid and Breast Surgery, Weifang Hospital of Traditional Chinese Medicine, Weifang, 261000, Shandong, China.
Xianqiang LiuDepartment of Thyroid and Breast Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong, China.
Changyuan DingDepartment of Thyroid Surgery, General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, China. sdushelding@163.com.
Xufu WangDepartment of Nuclear Medicine, The Affiliated Hospital of Qingdao University, Qingdao, 26603, Shandong, China. wangxufu@sina.com.
Haitao ZhengDepartment of Thyroid Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, 264000, Shandong, China. zhenghaitao1972@126.com.

Funding

the Technology Project of Medicine and Health Care in Shandong Province 202304081359
6 · The paper itself

Abstract

Many patients with medullary thyroid cancer (MTC) experience recurrent or persistent disease after surgery due to its aggressive nature. However, the prognostic factors for progression-free survival (PFS) have been poorly investigated. This study aimed to explore prognostic factors associated with PFS in patients with MTC. Patients with MTC were enrolled from 15 medical centers in Shandong Province, China, between January 2010 and December 2021. Univariate and multivariate Cox regression analyses were used to explore the prognostic factors for PFS in patients with MTC. Receiver operating characteristic curve analysis was performed to determine the optimal cutoff value of the metastatic lymph node ratio (LNR) in predicting PFS. Patients with MTC from the Surveillance, Epidemiology, and End Results (SEER) database were used to test the predictive value of the LNR cutoff for overall survival (OS) and disease-specific survival (DSS). In the Shandong cohort, extrathyroidal extension (HR, 1.622; 95% CI 1.022-2.575, P = 0.040), LNR (HR, 2.806; 95% CI 1.121-7.025, P = 0.028), and T3 stage (HR, 2.060; 95% CI 1.074-3.952, P = 0.030) were independent risk factors for PFS in patients with MTC. The optimal cutoff value of the LNR for predicting PFS was 0.19. Compared to patients with LNR < 0.19, those with LNR ≥ 0.19 suffered worse PFS (Log-rank P < 0.0001) in the Shandong cohort, and worse OS (Log-rank P < 0.0001) and DSS (Log-rank P < 0.0001) in the SEER cohort. This study identified prognostic factors for PFS in patients with MTC. LNR ≥ 0.19 could be used as an adverse prognostic factor for patients with MTC.

Indexed as

Carcinoma, NeuroendocrineThyroid NeoplasmsAdultAgedChinaCohort StudiesFemaleHumansLymphatic MetastasisLymph Node RatioMaleMiddle AgedNeoplasm StagingPrognosisProgression-Free SurvivalRetrospective StudiesExtrathyroidal extensionMedullary thyroid cancerMetastatic lymph nodes radioProgression free survival

Identifiers

PMID40392415

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.